Skip to main content
SpringerLink
Log in

Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The antitumor effects of chemotherapy, recombinant human interleukin-2 (IL-2), recombinant human interferon α A/D (IFNα), allogeneic human lymphokine-activated killer (LAK) cells, and antitumor monoclonal antibody (mAb), administered alone and in various combinations, were tested in athymic nude mice carrying human tumor xenografts. Treatment began 6–18 days after i.v. or i.p. inoculation of colorectal carcinoma or melanoma cell lines, when macroscopic growths were evident. Chemotherapy consisted of two or three courses of 5-fluorouracil (5-FU) or dacarbazine. IL-2 and/or IFNα were administered three to five times weekly for 1–3 weeks, usually starting 2–5 days after chemotherapy. Human LAK cells were infused once or twice weekly for 2 or 3 weeks concurrently with IL-2. In some experiments, murine anticolorectal carcinoma mAb (SF25) was administered. In both tumor systems, chemotherapy alone or immunotherapy alone (IL-2, IL-2 + LAK cells, IFNα, IL-2 + IFNα ± LAK cells) had little or no therapeutic effects. Additive effects were obtained by combining chemotherapy with IL-2 and LAK cells or with IL-2 and IFNα. In the majority of the experiments, the most effective combination was chemotherapy + IL-2 + IFNα + LAK cells. Treatment with mAb was beneficial in the colorectal carcinoma system when combined with 5-FU + IL-2 or 5-FU + IL-2 + IFNα. Homing experiments with radiolabeled human and mouse LAK cells injected i.v. showed increased early accumulation in the liver and lungs, whereas freshly explanted mouse splenocytes localized mostly in the spleen and liver. The tissue distribution pattern of human LAK cells was similar in normal and tumor-bearing mice (with lung metastases). These findings suggest that combination of chemotherapy with cytokines and LAK cells can be partially effective for advanced solid human tumors even in the absence of the host's T-cell immune response. Preliminary experiments showed that tumor-specific, anti-melanoma T-cell clones were effective in local (s.c.) tumor growth inhibition (Winn assay) following coinjection with the autologous tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR, Gucalp R, Atkins MB, Hawkins MJ (1990) High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 82: 1202–1206

    Google Scholar 

  2. Agah R, Malloy B, Sherrod A, Mazumder A (1988) Successful therapy of natural killer-resistant pulmonary metastases by the synergism of γ-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 48: 2245–2248

    Google Scholar 

  3. Baisch H, Otto U, Klöppel G (1990) Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor α and/or α interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies. Cancer Res 50: 6389–6395

    Google Scholar 

  4. Balkwill FR (1989) Interferons. Lancet 1: 1060–1063

    Google Scholar 

  5. Borden EC, Sondel PM (1990) Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65: 800–814

    Google Scholar 

  6. Brunda MJ, Bellantoni D, Sulich V (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40: 365–371

    Google Scholar 

  7. Bukowski RM, Murthy S, Sergi J, Budd GT, McKeever S, Medendorp SV, Tubbs R, Gibson V, Finke J (1990) Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-α2a: clinical effects. J Biol Response Mod 9: 538–545

    Google Scholar 

  8. Degiovanni G, Lahaye T, Herin M, Hainaut P, Boon T (1988) Antigenic heterogeneity of human melanoma detected by autologous CTL clones. Eur J Immunol 18: 671–676

    Google Scholar 

  9. Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH (1990) Recombinant interleukin-2 and adoptive cellular therapy alternated with decarbazine therapy in melanoma: a national biotherapy study group trial. J Natl Cancer Inst 82: 1345–1352

    Google Scholar 

  10. Dillman RO, Oldham RK, Tauer KW, Orr DW, Barth NM, Blumenschein G, Arnold J, Birch R, West WH (1991) Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a national biotherapy study group trial. J Clin Oncol 9: 1233–1240

    Google Scholar 

  11. Eggermont AMM, Sugarbaker PH (1988) Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer 58: 410–414

    Google Scholar 

  12. Eisenthal A, Cameron RB, Rosenberg SA (1990) Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-α and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144: 4463–4471

    Google Scholar 

  13. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1409

    Google Scholar 

  14. Faltynek CR, Oppenheim JJ (1988) Interferons in host defense. J Natl Cancer Inst 80: 151–153

    Google Scholar 

  15. Felgar RE, Hiserodt JC (1990) In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol 129: 288–298

    Google Scholar 

  16. Flaherty LE, Redman BG, Chabot GC, Martino S, Gualdoni SM, Heilbrun LK, Valdivieso M, Bradley EC (1990) A phase I–II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65: 2471–2477

    Google Scholar 

  17. Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621–1639

    Google Scholar 

  18. Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Mier JW, Caliendo G (1990) Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 82: 1397–1402

    Google Scholar 

  19. Giovanella BC, Fogh J (1985) The nude mouse in cancer research. Adv Cancer Res 44: 69–120

    Google Scholar 

  20. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281–355

    Google Scholar 

  21. Hamblin TJ, Davies B, Sadullah S, Oskam R, Palmer P, Franks CR (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cis-platin, interleukin-2 (IL-2) and alfa-interferon (IFN) (abstract). Proc Am Soc Clin Oncol 10: 294

    Google Scholar 

  22. Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39: 390–396

    Google Scholar 

  23. Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D (1990) Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8: 1657–1663

    Google Scholar 

  24. Iigo M, Nakajima Y, Nishikata K, Hoshi A (1989) Effects of interleukin-2 and interferon-α A/D treatment on lymphocytes from tumour-bearing mice. Br J Cancer 59: 883–888

    Google Scholar 

  25. Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, Ben-Basat H, Biran S, Schlesinger M, Franks CR, Roest G, Palmer P, Shiloni E (1992) Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine (DTIC) and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Immunol Lett (in press)

  26. Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T, Kishimoto S (1988) Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 48: 1173–1179

    Google Scholar 

  27. Kedar E, Weiss DW (1983) The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 38: 171–287

    Google Scholar 

  28. Kedar E, Ikejiri BL, Bonnard GD, Herberman RB (1982) A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses. Eur J Cancer 18: 991–1000

    Google Scholar 

  29. Kedar E, Ben-Aziz R, Shiloni E (1988) Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells. Isr J Med Sci 24: 494–504

    Google Scholar 

  30. Kedar E, Ben-Aziz R, Epstein E, Leshem B (1989) Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide: IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 29: 74–78

    Google Scholar 

  31. Kedar E, Lebendiker-Gazit Z, Tsuberi B, Ben-Aziz R, Epstein E, Weisz A, Rutkowski Y, Shiloni E, Shouval D, Weiss DW, Leshem B, Slavin S (1990) Cytokines increase the therapeutic efficacy of cancer chemotherapy and facilitate immunohematopoietic reconstitution following bone marrow transplantation: in: Adam A, Rubinstein E (eds) Recent advances in chemotherapy. Lewin-Epstein, Bat-Yam, pp 840.1–840.8

    Google Scholar 

  32. Kedar E, Rutkowski Y, Leshem B (1992) Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon α and the role of specific T-cells. Cancer Immunol Immunother (in press)

  33. Kellokumpu-Lehtinen P, Nordman E (1990) Recombinant interferon-α2a and vinblastine in advanced renal cell cancer: a clinical phase I–II study. J Biol Response Mod 9: 439–444

    Google Scholar 

  34. Knuth A, Danowski B, Oettgen HF, Old LJ (1984) Cell mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2 dependent T-cell cultures. Proc Natl Acad Sci USA 81: 3511–3514

    Google Scholar 

  35. Knuth A, Wölfel T, Kleeman E, Boon T, Meyer zum Buschenfelde KH (1989) Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 86: 2804–2808

    Google Scholar 

  36. Koh HK (1991) Cutaneous melanoma. N Engl J Med 325: 171–182

    Google Scholar 

  37. Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J (1989) Concomitant administration of recombinant human interleukin-2 and recombinant interferon α-2A in cancer patients: a phase I study. J Clin Oncol 7: 1726–1732

    Google Scholar 

  38. MacDonald HR, Blanc C, Lees RK, Sordat B (1986) Abnormal distribution of T cell subsets in athymic mice. J Immunol 136: 4337–4339

    Google Scholar 

  39. Maghazachi AA, Goldfarb RH, Kitson RP, Hiserodt JC, Giffen CA, Herberman RB (1990) In vivo tissue distribution of interleukin-2 activated cells. In: Lotzova E, Herberman RB (eds) Interleukin-2 and killer cells in cancer. CRC Reviews, CRC, Boca Raton, p 260

    Google Scholar 

  40. Marincola FM, Drucker BJ, Keeling CA, Siao DY, Fletcher Starnes H, Goodwin DA, Holder WD (1989) The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice. Surgery 105: 79–85

    Google Scholar 

  41. McIntosh JK, Mulè JJ, Krosnick JD, Rosenberg SA (1989) Combination cytokine immunotherapy with tumor necrosis factor α, interleukin-2, and α-interferon and its synergistic antitumor effects in mice. Cancer Res 49: 1408–1414

    Google Scholar 

  42. Mitchell MS (1988) Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 80: 1445–1450

    Google Scholar 

  43. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 6: 409–424

    Google Scholar 

  44. Mulder NH, Willemse PHB, Schraffordt Koops H, de Vries EGE, Sleijfer D Th (1990) Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer 62: 1006–1007

    Google Scholar 

  45. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489

    Google Scholar 

  46. Neville ME (1987)51Cr-uptake assay. A sensitive and reliable method to quantitate cell viability and cell death. J Immunol Methods 99: 77–80

    Google Scholar 

  47. Notter M, Schirrmacher V (1990) Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells. Int J Cancer 45: 834–841

    Google Scholar 

  48. Oomori K, Kikuchi Y, Miyauchi M, Kite T, Iwano I, Kizawa I, Hirata J, Kuki E (1989) Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 115: 217–220

    Google Scholar 

  49. Ortaldo JR, Porter HR, Miller P, Stevenson HC, Ozols RF, Hamilton TC (1986) Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Cancer Res 46: 4414–4419

    Google Scholar 

  50. Paciucci PA, Ryder JS, Holland JF (1990) Correlation between clinical activity of IL-2 and anti-tumor effects in vitro during the first week of therapy (abstract). Proc Am Soc Clin Oncol 9: 201

    Google Scholar 

  51. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA (1988) Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48: 122–129

    Google Scholar 

  52. Parkinson DR (1990) Interleukin-2: further progress through greater understanding. J Natl Cancer Inst 82: 1374–1376

    Google Scholar 

  53. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, Atkins MB, Hawkins MJ (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8: 1650–1656

    Google Scholar 

  54. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J, Levin B (1990) Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027–2031

    Google Scholar 

  55. Richards JM, Priest E, Hamasaki V, Skosey P, Ramming K (1991) Sequential chemoimmunotherapy for metastatic melanoma (abstract). Proc Am Soc Clin Oncol 10: 298

    Google Scholar 

  56. Rosenberg SA, Longo DL, Lotze MT (1989) Principles and applications of biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 3rd edn Lippincott, Philadelphia, pp 301–347

    Google Scholar 

  57. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485

    Google Scholar 

  58. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874

    Google Scholar 

  59. Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, Whiteside TL (1990) Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin-2. Cancer Res 50: 3113–3118

    Google Scholar 

  60. Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R, Shiloni E (1991) Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 9: 1687–1691

    Google Scholar 

  61. Takahasi H, Wilson B, Ozturk M, Motté P, Strauss W, Isselbacher KJ, Wands JR (1988) In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen. Cancer Res 48: 6573–6579

    Google Scholar 

  62. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473–3486

    Google Scholar 

  63. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50: 5735–5739

    Google Scholar 

  64. Watanabe N, Niitsu Y, Yamauchi N, Umeno H, Sone H, Neda H, Urushizaki I (1988) Antitumor synergism between recombinant human tumor necrosis factor and recombinant human interferon-γ. J Biol Response Mod 7: 24–31

    Google Scholar 

  65. Wiltrout RH, Salup RR (1988) Adoptive immunotherapy in combination with chemotherapy for cancer treatment. Prog Exp Tumor Res 32: 128–153

    Google Scholar 

  66. Winkelhake JL, Stampfl S, Zimmerman RJ (1987) Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 47: 3948–3953

    Google Scholar 

  67. Yoneda K, Yamamoto T, Osaki T (1989) Influence of interferon on adriamycin uptake of cultured tumor cells. Int J Cancer 44: 483–488

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel

    Zulma Gazit, David W. Weiss, Michal Yechezkeli & Eli Kedar

  2. The Liver Unit, Hadassah Medical Center, Jerusalem, Israel

    Daniel Shouval

  3. The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany

    Volker Schirrmacher, Michael Notter & Jürgen Walter

Authors
  1. Zulma Gazit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Shouval
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michal Yechezkeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Volker Schirrmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Notter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jürgen Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eli Kedar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gazit, Z., Weiss, D.W., Shouval, D. et al. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35, 135–144 (1992). https://doi.org/10.1007/BF01741861

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741861

Key words

Search

Navigation